A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

NCT07646535 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Aldosteronism

Interventions

DRUG: SAL0140 Tablets
DRUG: SAL0140 Tablets
DRUG: SAL0140 placebo

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.